NKTR•benzinga•
Nektar Therapeutics To Sell Its Commercial PEGylation Reagent Manufacturing Business To Ampersand Capital Partners For $90M Total Consideration, Comprised Of $70M In Cash and $20M Equity Ownership In New Portfolio Company
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 4, 2024 by benzinga